Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?

Passhak, Maria; McNamara, Mairéad G.; Hubner, Richard A.; Ben-Aharon, Irit; Valle, Juan W.

doi:10.1016/j.beem.2023.101836

Cited by 4 publications

(2 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This aberrant activation of RTK pathways contributes to the dysregulation of key cellular processes such as proliferation, survival, and angiogenesis, further underscoring their potential as therapeutic targets in NETs. Currently, only Everolimus and sunitinib, both related to RTK inhibition, have been approved for targeted therapy in NETs [56]. These agents have shown efficacy in certain subsets of NETs, but their clinical benefits are often limited by adverse effects and acquired resistance.…”

Section: Discussionmentioning

confidence: 99%

Exploring Emerging Therapeutic Targets and Opportunities in Neuroendocrine Tumors: Updates on Receptor Tyrosine Kinases

Toffoli,

Ditsiou,

Gagliano

2024

Receptors

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) represent a diverse group of neoplasms originating from neuroendocrine cells, presenting varied clinical behaviors and posing significant challenges in management. This review explores the emerging roles of receptor tyrosine kinases (RTKs) in the pathogenesis and progression of NETs, including vascular endothelial growth factor receptors (VEGFRs), insulin-like growth factor receptors (IGF-1R), RET, epidermal growth factor receptor (EGFR), and ALK. The dysregulation of RTK signaling pathways contributes to key cellular processes such as proliferation, survival, and invasion in NETs. We discuss the potential of targeting RTKs as therapeutic strategies in NETs, with a focus on recent developments in RET inhibitors and the therapeutic implications of RTK alterations.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring Emerging Therapeutic Targets and Opportunities in Neuroendocrine Tumors: Updates on Receptor Tyrosine Kinases

Toffoli,

Ditsiou,

Gagliano

2024

Receptors

View full text Add to dashboard Cite

show abstract

“…As part of the standard therapy sequence for NENs, long-acting SSAs, such as octreotide and lanreotide, are provided to subjects with positive somatostatin receptors. They represent a significant part of medical management before and after surgery, an alternative to surgery in inoperable cases, or a long-term management option for NENs that have been recently described as "resistant" (tumours that display symptom progression and metastatic spreading despite standard care treatment) [1,2,6,27].…”

Section: The Use Of Somatostatin Analogues (Ssas)mentioning

confidence: 99%

Neuroendocrine Neoplasia: From Pathophysiology to Novel Therapeutic Approaches

Carsote,

Nistor

2024

Biomedicines

View full text Add to dashboard Cite

show abstract

Update in the management of gastroenteropancreatic neuroendocrine tumors

Sedlack,

Varghese,

Naimian

et al. 2024

Cancer

View full text Add to dashboard Cite

Neuroendocrine neoplasms are a diverse group of neoplasms that can occur in various areas throughout the body. Well‐differentiated neuroendocrine tumors (NETs) most often arise in the gastrointestinal tract, termed gastroenteropancreatic neuroendocrine tumors (GEP‐NETs). Although GEP‐NETs are still uncommon, their incidence and prevalence have been steadily increasing over the past decades. The primary treatment for GEP‐NETs is surgery, which offers the best chance for a cure. However, because GEP‐NETs are often slow‐growing and do not cause symptoms until they have spread widely, curative surgery is not always an option. Significant advances have been made in systemic and locoregional treatment options in recent years, including peptide‐receptor radionuclide therapy with α and β emitters, somatostatin analogs, chemotherapy, and targeted molecular therapies.

show abstract

Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?

Cited by 4 publications

References 70 publications

Exploring Emerging Therapeutic Targets and Opportunities in Neuroendocrine Tumors: Updates on Receptor Tyrosine Kinases

Exploring Emerging Therapeutic Targets and Opportunities in Neuroendocrine Tumors: Updates on Receptor Tyrosine Kinases

Neuroendocrine Neoplasia: From Pathophysiology to Novel Therapeutic Approaches

Update in the management of gastroenteropancreatic neuroendocrine tumors

Contact Info

Product

Resources

About